The US Alcohol and Tobacco Tax and Trade Bureau (TTB) warned alcoholic drinks manufacturers to limit the use of the word "clean" to describe a flavor, not to imply health claims.
All alcoholic beverages must also bear a health risk warning, according to the TTB's existing labeling requirements, and the word "clean" isn't a method to soften that message.
The TTB admitted that its regulations do not define the word 'clean,' and that they do not have standards for the use of the term on labels or in advertisements.
It warned that consumers should not interpret the term as meaning that the beverage is organic or has met other production standards set by TTB.
The TTB noted that the word clean is being used along with other teams to create the misleading impression that consuming the alcoholic beverage will have health benefits, or that the health risks of alcohol consumption will be mitigated.


Maduro Faces Rare Narcoterrorism Charges in U.S. Court
Valero Port Arthur Refinery Explosion Prompts $1M Lawsuit Over Worker Safety Negligence
Meta Ties Executive Pay to Aggressive Stock Price Targets in Major Retention Push
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026
Stellantis Shareholder Fraud Lawsuit Dismissed by U.S. Judge
Novo Nordisk Shares Tumble After CagriSema Misses Key Trial Endpoint
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio
Google's TurboQuant Algorithm Sends Memory Chip Stocks Tumbling
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval
Merck Raises Growth Outlook, Targets $70 Billion Revenue From New Drugs by Mid-2030s
xAI Faces Federal Lawsuit Over Grok AI-Generated Child Sexual Abuse Material
UBS Seeks Legal Protection Over Credit Suisse's Nazi-Era Banking Activities
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Federal Reserve Hires Robert Hur to Fight DOJ Subpoenas Targeting Jerome Powell
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal 



